STAANasdaqOphthalmic GoodsFiscal year ends January 2

STAAR SURGICAL CO

Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 12, 2026

$21.88+0.61 (+2.87%)

Close on Oct 19, 2026

Market cap: $1.13B
P/E (TTM): 312.6
Dividend yield: –

Debt

Borrowings on the balance sheet, Jul 3, 2026

Staar Surgical reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Staar Surgical's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Staar Surgical's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-2 reverse split on May 18, 1992
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is STAA.

Revenue growth51.3% · median 8.9%

Gross margin76.6% · median 71.3%

Operating margin4.0% · median 6.1%

Net margin1.1% · median -1.2%

Company	Revenue	Growth
ALC	$7.18B	+10.5%
BLCO	$5.32B	+8.9%
COO	$4.24B	+4.7%
WRBY	$911.61M	+11.0%
STAA	$339.59M	+51.3%
RXST	$127.58M	-13.2%

Company

Exchange: Nasdaq
Industry: Ophthalmic Goods
Fiscal year ends: January 2
Employees: 957
Held by institutions: 100.0%
Auditor: BDO USA, P.C.
SEC CIK: 718937

Advertisement
300 × 250